Cure My Disease

Don't miss your cure!

 Log in / Sign up

Belzutifan extension trial aims to extend lives in VHL and advanced cancer

NCT ID NCT07405164

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 10 times

Summary

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by mouth daily until their disease gets worse or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Belzutifan (a drug that blocks a protein helping tumors grow)
What this could lead to
If successful, this trial could show that belzutifan helps people with VHL disease or advanced solid tumors live longer while managing their cancer over time.
What could go wrong
This is an extension study, so it only includes people already on belzutifan. It is not testing a new treatment, and results may not apply to everyone. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm renal cell adenocarcinoma renal cell carcinoma von Hippel-Lindau disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, RENAL CELL MALIGNANT NEOPLASMS VON HIPPEL-LINDAU DISEASE

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Asan Medical Center ( Site 2900)

    RECRUITING

    Seoul, 05505, South Korea

  • Auckland City Hospital ( Site 3000)

    RECRUITING

    Auckland, 1023, New Zealand

  • BP - A Beneficencia Portuguesa de São Paulo ( Site 0200)

    RECRUITING

    São Paulo, São Paulo, 01323-001, Brazil

  • Beth Israel Deaconess Medical Center ( Site 0107)

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Bradfordhill ( Site 0301)

    RECRUITING

    Santiago, Region M. de Santiago, 8420383, Chile

  • CIDO SpA ( Site 0305)

    RECRUITING

    Temuco, Araucania, 4810148, Chile

  • CNCE Precarpathian Clinical Oncologic Center ( Site 2600)

    ACTIVE_NOT_RECRUITING

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine

  • Dana-Farber Cancer Institute ( Site 0105)

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • FALP ( Site 0300)

    RECRUITING

    Santiago, Region M. de Santiago, 7500921, Chile

  • Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 1000)

    RECRUITING

    Olomouc, 77900, Czechia

  • Fred Hutchinson Cancer Center ( Site 0106)

    RECRUITING

    Seattle, Washington, 98109, United States

  • Gustave Roussy ( Site 1701)

    RECRUITING

    Villejuif, Val-de-Marne, 94805, France

  • Hadassah Medical Center ( Site 1604)

    RECRUITING

    Jerusalem, 9112001, Israel

  • Herlev and Gentofte Hospital ( Site 1200)

    RECRUITING

    Herlev, Capital Region, 2370, Denmark

  • Hospital Universitari Vall d'Hebron ( Site 2300)

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre ( Site 2301)

    RECRUITING

    Madrid, 28041, Spain

  • Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 0100)

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Hôpitaux Universitaires de Strasbourg ( Site 1702)

    RECRUITING

    Strasbourg, Bas-Rhin, 67200, France

  • Imperial College Healthcare NHS Trust, Charing Cross Hospital ( Site 2504)

    ACTIVE_NOT_RECRUITING

    London, London, City of, W6 8RF, United Kingdom

  • Institut Claudius Regaud ( Site 1703)

    RECRUITING

    Toulouse, Haute-Garonne, 31059, France

  • Isala, locatie Zwolle ( Site 1902)

    RECRUITING

    Zwolle, Overijssel, 8025 AB, Netherlands

  • James Lind Centro de Investigacion del Cancer ( Site 0304)

    RECRUITING

    Temuco, Araucania, 4800827, Chile

  • Karmanos Cancer Center ( Site 0108)

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Kyushu University Hospital ( Site 3101)

    RECRUITING

    Fukuoka, 812-8582, Japan

  • ME І.І. Mechnykov Dnipro Regional Clinical Hospital ( Site 2601)

    RECRUITING

    Dnipropetrovsk, Dnipropetrovsk Oblast, 49005, Ukraine

  • Maastricht Universitair Medisch Centrum - MUMC ( Site 1900)

    RECRUITING

    Maastricht, Limburg, 6229 HX, Netherlands

  • N.N. Blokhin NMRCO ( Site 2101)

    ACTIVE_NOT_RECRUITING

    Moscow, Moscow, 115478, Russia

  • ONCOCENTRO APYS ( Site 0302)

    RECRUITING

    Viña del Mar, Valparaiso, 2520598, Chile

  • Oncovida ( Site 0303)

    RECRUITING

    Santiago, Region M. de Santiago, 7500994, Chile

  • Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 1501)

    RECRUITING

    Budapest, 1122, Hungary

  • ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2502)

    RECRUITING

    London, London, City of, SW3 6JJ, United Kingdom

  • Rabin Medical Center ( Site 1602)

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus ( Site 1600)

    RECRUITING

    Haifa, 3109601, Israel

  • Russian Scientific Center of Radiology and Surgical Technologies ( Site 2100)

    ACTIVE_NOT_RECRUITING

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • SCRI Oncology Partners ( Site 7000)

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • START San Antonio ( Site 0104)

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Samsung Medical Center ( Site 2902)

    RECRUITING

    Gangnam, Seoul, 06351, South Korea

  • Severance Hospital, Yonsei University Health System ( Site 2901)

    RECRUITING

    Seodaemun-gu, Seoul, 03722, South Korea

  • Sheba Medical center ( Site 1601)

    RECRUITING

    Ramat Gan, 5265601, Israel

  • Sourasky Medical Center ( Site 1603)

    RECRUITING

    Tel Aviv, 64239, Israel

  • St Bartholomew's Hospital ( Site 2500)

    RECRUITING

    London, London, City of, EC1A 7BE, United Kingdom

  • St George Hospital-Oncology Clinical Research Unit ( Site 2701)

    RECRUITING

    Kogarah, New South Wales, 2217, Australia

  • Taipei Veterans General Hospital ( Site 2800)

    ACTIVE_NOT_RECRUITING

    Taipei, 11217, Taiwan

  • Tampereen yliopistollinen sairaala ( Site 1305)

    RECRUITING

    Tampere, Pirkanmaa, 33520, Finland

  • The Beatson West of Scotland Cancer Centre ( Site 2505)

    RECRUITING

    Glasgow, Glasgow City, G12 0YN, United Kingdom

  • The Christie NHS Foundation Trust ( Site 2501)

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • UZ Leuven ( Site 0900)

    RECRUITING

    Leuven, Vlaams-Brabant, 3000, Belgium

  • Westmead Hospital ( Site 2703)

    RECRUITING

    Sydney, New South Wales, 2145, Australia

  • Zakład Diagnostyki Laboratoryjnej, Centrum Onkologii ( Site 2000)

    RECRUITING

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.